Rani Therapeutics Holdings Inc (RANI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rani Therapeutics Holdings Inc (RANI) has a cash flow conversion efficiency ratio of -0.183x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.50 Million) by net assets ($35.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RANI company net worth for the company's overall valuation and market capitalisation.
Rani Therapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Rani Therapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rani Therapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rani Therapeutics Holdings Inc ranked by their cash flow conversion efficiency. See RANI operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Surya Pertiwi Tbk
JK:SPTO
|
0.021x |
|
FutureChem Co.Ltd
KQ:220100
|
0.000x |
|
Technical Olympic S.A
AT:OLYMP
|
-0.002x |
|
Sahacogen (Chonburi) Public Company Limited
BK:SCG
|
0.017x |
|
Se Gyung Hi Tech Co.Ltd
KQ:148150
|
0.004x |
|
Roadzen Inc.
NASDAQ:RDZN
|
0.000x |
|
Patriot One Technologies Inc
F:0PL
|
-0.493x |
|
Scope Fluidics SA
WAR:SCP
|
-0.102x |
Annual Cash Flow Conversion Efficiency for Rani Therapeutics Holdings Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rani Therapeutics Holdings Inc from 2019 to 2025. View Rani Therapeutics Holdings Inc (RANI) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $41.51 Million | $-18.71 Million | -0.451x | +95.56% |
| 2024-12-31 | $3.49 Million | $-35.50 Million | -10.162x | -404.63% |
| 2023-12-31 | $25.44 Million | $-51.24 Million | -2.014x | -220.38% |
| 2022-12-31 | $74.00 Million | $-46.52 Million | -0.629x | -136.97% |
| 2021-12-31 | $121.57 Million | $-32.24 Million | -0.265x | -300.95% |
| 2020-12-31 | $-113.34 Million | $-14.96 Million | 0.132x | -51.44% |
| 2019-12-31 | $-96.64 Million | $-26.27 Million | 0.272x | -- |
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug subst… Read more